Skip to content

Immunotherapy of Chronic Kidney Failure

Phase II Trial of V8 in Treating Kidney Failure

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04377243
Enrollment
20
Registered
2020-05-06
Start date
2020-06-16
Completion date
2021-09-01
Last updated
2020-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Failure Chronic

Brief summary

Kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self. There are many causes to this, but abnormal kidney function tests, i.e., BUN and creatinine, can reveal the disease. Oral delivery of kidney cells is ought to produce the immune tolerance - phenomenon is known as oral tolerance. Preliminary studies produced convincing evidence that this hypothesis holds true and has not produced any adverse side effects. Intended open label Phase II aims to confirm these findings.

Interventions

BIOLOGICALV8

one pill per day either V8 or placebo

Sponsors

Immunitor LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

neither patients nor attending physician are aware

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Baseline level of creatinine twice above normal

Exclusion criteria

* Baseline level of creatinine normal

Design outcomes

Primary

MeasureTime frameDescription
Effect on creatinine1 monthChange in serum creatinine level from baseline

Countries

Mongolia

Contacts

Primary ContactAldar Bourinbaiar, MD/PhD
aldar@immunitor.com13014760930
Backup ContactMarina Tarakanovskaya, MD
info@immunitor.com+97695130306

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026